Ask AI
ProCE Banner Activity

AJX-101: Phase I Study of AJ1-11095, a Type II JAK2 Inhibitor, in Patients With Myelofibrosis After Prior Type I JAK2 Inhibitor Treatment

Conference Coverage
Slideset

In the dose-escalation phase I AJX-101 study, the novel type II JAK2 inhibitor AJ1-11095 was associated with a manageable safety profile and improvement in spleen volume and symptoms in patients with myelofibrosis after failure of a type I JAK2 inhibitor.

Released: June 26, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with hematologic malignancies. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from studies of hematologic malignancies at ASCO 2026 and EHA 2026 along with expert guidance to optimize personalized care and improve patient outcomes

  • Utilize prognostic and predictive biomarkers to accurately identify patients with hematologic malignancies most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for hematologic malignancies to accelerate their effective incorporation into clinical practice

  • Support informed shared decision-making for patients with hematologic malignancies through accessible discussion of the potential clinical implications of recently presented data at ASCO 2026 and EHA 2026